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Anti—glomerular basement membrane antibody-induced glome-
rulonephritis. Sixty-three glomerulonephritic patients with evi-
dence of anti—glomerular basement membrane (GBM) antibody
by immunofluorescence, elution of specific antibody and/or
detection of circulating antibody arc reviewed. Thirty-Iwo of the
patients had concomitant pulmonary manifestations (hemorrhage
and/or pulmonary failure) compatible with Goodpasture's
syndrome, 21 had only glomerulonephritis, and ten without prior
immunopathologic studies had antiGBM antibodies in renal
transplants and no history of pulmonary symptoms. The majority
of the patients were young males who succumbed to the disease
process or required dialysis and/or transplantation. Five males
and two females did not develop permanent renal insufficiency.
Bilateral nephrectomy (19 patients) was felt to be helpful or
life-saving in seven patients; however, six patients had continued
pulmonary symptoms after nephrectomy, contributing to death
in three cases. Five of 13 nonnephrectomized or unilaterally
nephrectomized individuals died in pulmonary failure. Immuno-
suppressive therapy was not generally helpful. Circulating anti-
GBM antibodies persisted for an average of six to eight months
after bilateral nephrectomy. Transplantation was usually success-
ful when delayed until circulating antiGBM antibodies had
declined; however, evidence of recurrent glomerulonephritis
developed in 19, possibly 20, of 34 transplanted patients, resulting
in graft failure in seven, possibly eight, instances.
Glomérulonéphrite induite par des anticorps anti membrane
basale. Soixante trois malades atteints de glomérulondphrite ott
l'anticorps anti membrane basale (GBM) a été mis en evidence
par immunofluorescence, élution de l'anticorps specifique et/ou
detection de l'anticorps circulant sont étudiés. Trente trois de
ces malades avaient des manifestations pulmonoaires conco-
mitantes (hemorragie et/ou insuffisance respiratoire) compatible
avec un syndrome de Goodpasture, 21 avaient une gloméru-
lonéphrite isoltte, dix enfin, qui n'avaient pas eu d'etude immuno-
pathologique antérieure, avaient des anticorps anti GBM dans
des reins transplanttts et aucun symptome pulmonaire. La
majorité des malades tttaient de jeunes hommes qui décédérent
du fait de Ia maladie ou durent étre httmodialysés et/ou trans-
plantés. Cinq hommes et deux femmes n'eurent pas d'insuffisance
rénale. La néphrectomie bilatérale (19 malades) fut jugée utile
ou indispensable chez sept malades. Cependant six d'entre eux
eurent des symptomes pulmonaires persistants aprés Ia néphrec-
tomie, manifestations qui contribuèrent a la mort dans trois cas.
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Cinq parmi les 13 malades non néphrectomisés ou unilatérale-
ment néphrectomisés moururent d'insuffisance pulmonaire. Le
traitemenl immunosuppresseur n'a pas été favorable dans
l'ensemble. Les anticorps anti GBM circulants ont persisté six
a huit mois, en moyenne, aprés la néphrectomie bilatérale. La
transplantation a réussi habituellement quand elle a été retardée
jusqu'à la diminution des anticorps circulants anti GBM.
Cependant des signes de glomérulonéphrite récurrente sont
apparus chez 19, et peut-étre 20, parmi les 34 malades transplan-
tés, conduisant a l'echee du transplant dans sept cas et peut-
être huit.
Immunoglobulins demonstrable by immunofluorescence
as linear deposits along the glomerular basement membrane
(GBM) have been found in certain cases of human gb-
merulonephritis [1—7]. The finding of immunoglobulins
in this pattern suggests the presence of antibodies reacting
with the GBM, so-called antiGBM antibodies, analogous
to heterologous, nephrotoxic (antiGBM) antibodies [8] or
autologous antiGBM antibodies produced in experimental
animals [9, 10]. In 1967, Lerner, Olassock and Dixon [11]
confirmed the etiologic role of antiGBM antibodies in a
group of patients with glomerulonephritis with and without
associated pulmonary hemorrhage (Goodpasture's syn-
drome [12—14]). These investigators were able to transfer
glomerulonephritis to subhuman primates with antiGBM
antibodies obtained from serum or dissociated from the
GBM of renal homogenates by elution in acid pH. Further
confirmation of the immunopathogenic role of antiGBM
antibodies in human gbomerubonephritis came when gb-
merular injury was accidentally induced in a renal homo-
graft placed in a patient in whom circulating antiGBM
antibodies had become detectable after nephrectomy
preparatory to transplantation [11], and other examples
are reported herein.
We have now had the opportunity to study 63 cases of
antiGBM nephritis from contributors throughout the
United States and Europe. The diagnoses have been
established by identification of the classical linear immuno-
fluorescent pattern of immunogbobulin deposition in
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glomeruli, elution of specific antibodies from the kidney [11]
and/or detection of circulating antiGBM antibodies [15].
Within the limits of information derived from clinical
summaries and questionnaires, this immunopathologic
information is correlated with clinical presentation, course
of the disease, outcome, response to therapy including
nephrectomy and feasibility of transplantation.
Methods
The patients with glomerulonephritis reported herein
were identified in part from the routine study of renal
tissues and/or sera submitted largely from transplantation
centers and transplant-oriented nephrology groups.
Renal tissues and/or sera from patients suspected of
having antiGBM glomerulonephritis because of rapidly
progressive courses of disease and/or associated hemoptysis
were also accepted for study, potentially increasing the
incidence of this immunopathogenic mechanism in the
group reported. Similar studies were done on patients
after renal transplantation.
Immunopathologic studies. Immunofluorescence was
done on cryostat kidney sections washed in phosphate-
buffered saline (PBS) and fixed in ether:ethyl alcohol
(51:50) and ethyl alcohol (absolute). After fixation, the
sections were rewashed and stained with fluorescein iso-
thiocyanate (FITC) conjugated [16, 17] antisera specific
by gel diffusion analysis for human IgG, IgA, 1gM,
complement (C 3), fibrinogen/fibrin and albumin. Specificity
of positive staining reactions was shown by absorption of
the reagents with their specific antigens and by blocking
with non-fluoresceinated specific antibodies. Sections
were examined with Zeiss RA or Universal microscopes
employing HBO 200 watt light sources, dark field illumin-
ation and UGI or BG12 excitation filters with appropriate
barriers. More recently, the FITC interference filter
system with optional incident illumination using dichroic
mirrors has been added, particularly for photography.
When sufficient renal tissue was available, isolation of
specific antiGBM antibodies was attempted by elution.
Each cortex was diced and homogenized in a chilled
Waring Blender orOmnimixer and the sediment (2000x G)
washed extensively in PBS. After a single wash in distilled
water to desalt the washed homogenate, it was eluted
twice in 0.02 M citrate buffer, pH 3.2 (20 parts buffer to
1 part homogenate) with constant stirring for 60 minutes
at room temperature. The eluate was immediately neutral-
ized with 0.1 N NaOH and allowed to stand overnight at
40 C. The cloudy precipitate which formed [11] upon
standing was removed by centrifugation (2000x G), and
the eluate was concentrated by negative pressure dialysis.
The IgG content of the eluate was determined by radial
diffusion in gel [18]. The presence of antiGBM antibodies
was detected in the concentrated eluate by indirect immuno-
fluorescence with normal human or primate kidney
cryostat sections as targets.
Circulating antiGBM antibodies were detected by
indirect immunofluorescence with normal renal target
tissues as described previously [15]. To increase the sensitiv-
ity of detection in some cases, arterial blood from patients'
arterial venous dialysis shunts was perfused through a
normal human or primate kidney. AntiGBM antibodies
were then detected by direct immunofluorescent comparison
of sections of the kidney obtained before and after perfu-
sion.
Clinical information. Clinical summaries were sought
from the referring physicians of all patients on whom
tissues and/or sera were submitted. In an attempt to
gather more standardized information, a questionnaire
completed by the patients' physicians was also requested.
Routine histologic sections from some patients were made
available for study.
Results
General. A total of 63 patients with evidence of antiGBM
antibodies were found during the routine examination of
renal tissues from approximately 900 patients, including
some whose tissues or sera were sent specifically for
confirmation of these antibodies. The incidence of this
immunopathogenic mechanism in the general population
can only be estimated from the percentages in this group.
Early in the study, when the patient sample was more
selective, evidence of antiGBM antibodies was found in
approximately 15 % of specimens. In recent years, as the
patient population studied has become more random, the
incidence has fallen to about 5 %. Since patients in whom
antiGBM antibody nephritis is suspected continue to be
sent for study, this latter figure may be erroneously
high, and an estimate of 3 to 5% would probably be
closer to the incidence of antiGBM nephritis in the general
nephritic population.
Of the patients reported here, 32 had clinical pictures
compatible with Goodpasture's syndrome (glomerulo-
nephritis with pulmonary hemorrhage). Twenty-one had
only glomerulonephritis and will be referred to throughout
the paper as non-Goodpasture's patients. Ten patients
without prior immunopathologic studies or histories of
pulmonary symptoms had antiGBM antibodies in renal
homografts. Five diabetic patients with linear immuno-
globulin deposits in glomeruli were excluded because
corroborative sera or elution studies were not available
to rule out nonspecific linear staining in this group as
reported by others [19, 20]. An additional eight renal
specimens, including two transplants, three perfused but
not transplanted normal kidneys and three autopsied
kidneys from patients dying of nonrenal disease, contained
striking linear deposits of immunoglobulin which could
not be confirmed to be antiGBM antibodies when elution
studies were done. Similar findings in kidneys at autopsy
have been reported by Koffler et al [21].
• •
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Fig. 1. A) Smooth continuous linear deposits of IgG are seen along a structurally intact GBM from patient 22. (FITC conjugated anti-
human IgG, original magnification x 400.) B) Somewhat irregular linear (arrow) deposits of IgG appear along the remnants of a severely
damaged GBM of patient 8. The capillary loops are compressed by extensive crescent formation (c). The staining was confirmed to be
antiGBM antibodies by elution and sera studies. The autofluorescent internal elastic lamina of a vessel (v) was free of immunofluores-
cent deposits. (FITC conjugated antihuman IgG, original magnification x 250.) C) Scant irregular IgG deposits are seen in a partially
hyalinized glomerulus (g) from patient 50. Linear staining of TBM (arrows) suggested the presence of antiGBM antibodies, which was
confirmed by elution and serum studies. (FITC conjugated antihuman IgG, original magnification x 250.) D) Indirect immunofluores-
cence detected antiGBM antibodies eluted from nephrectomized kidney of patient 7. Intense staining is present along the GBM and the
TBM of "islands" of tubules. Less intense staining is seen along Bowman's capsule of this normal human kidney section. (F1TC
conjugated antihuman IgG, original magnification x 400.) E) Smooth linear deposits of IgG conform to the distribution of alveolar
basement membranes in the lung of patient 12 with Goodpasture's syndrome. (FITC conjugated antihuman IgG, original magnification
x400.)
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Immunofluorescent studies. Renal tissues from 27 patients
with evidence of antiGBM antibodies and Goodpasture's
syndrome were available for direct immunofluorescent
study. Likewise, 18 renal samples from patients with
non-Goodpasture's antiGBM nephritis were studied. Seven
transplant biopsies from Goodpasture's and non-Good-
pasture's patients and ten transplant biopsies from patients
with linear deposits but without pretranspiant immuno-
pathologic characterization were also examined. IgG was
present conforming to the distribution of the GBM in all
but two instances. When present in relatively well preserved
glomeruli, the patterns of staining were smooth, continuous
and linear (Fig. 1). In kidneys with advanced glomerular
architectural disruption, the GBM lost its characteristic
ribbonlike structure and became corrugated, crumpled
and interrupted in areas, so that the classical linear staining
pattern was no longer possible (Fig. 1). In only a few
instances, however, was there any difficulty in differentiat-
ing the staining pattern from the so-called granular deposits
usually associated with immune complex deposition. In
some kidneys containing a mixture of hyalinized and less
damaged glomeruli, variable staining was present with
negative hyalinized glomeruli adjacent to intensely stained,
better preserved glomeruli. The need for adequate specimens
to avoid sampling errors is emphasized by this observation.
Two severely damaged kidneys [one Goodpasture's
(patient 28) and one non-Goodpasture's (patient 50)]
contained only small amounts of IgG in an irregular
segmental pattern atypical of antiGBM antibodies.
However, these kidneys were later confirmed by elution
studies to contain antiGBM antibodies.
The intensity of linear staining was such that it could
be differentiated easily from the faint IgG accentuation
of the GBM identified occasionally in renal biopsies lacking
other evidence of antiGBM antibodies. This latter GBM
accentuation may merely represent the detection of a small
amount of IgG associated normally with the GBM [221
and now detectable with improved reagents and immuno-
fluorescent equipment.
IgG was occasionally present in a linear fashion along
Bowman's capsule and more commonly along tubular
basement membranes (TBM) in foci or "islands" of renal
tubules, suggesting that an antigen cross-reactive with the
GBM was shared by Bowman's capsule and a portion of
the TBM. The TBM deposits were more frequent in
kidneys from patients with Goodpasture's syndrome as
noted previously [23] in a comparative study of eluates
from Goodpasture's and non-Goodpasture's glomerulo-
nephritic kidneys.
Segmental IgA was found in one of 17, zero of seven
and one of nine Goodpasture's, non-Goodpasture's and
transplant specimens so studied. Irregular and segmental
deposits of 1gM were somewhat more common, being
found in three of 20, three of nine and four of nine Good-
pasture's, non-Goodpasture's and transplant specimens,
respectively. Fibrin/fibrinogen deposits were not frequent
Table 1. Comparison of IgG and C3 immunofluorescent deposits
in renal specimens
.Patient
IgG
equals
C3
less
than
IgG
IgG
only
Goodpasture's syndrome 6 12 4
Non-Goodpasture's glomerulonephritis 4 5 4
Renal transplants 7 5 4
or striking other than in areas of crescent formation. When
present in glomeruli, the fibrin/fibrinogen was present in a
minimal and irregular intracapillary pattern.
Complement (C3) accompanied the IgG deposits in the
majority of instances (Table 1), but the staining was often
much less intense and tended to be segmental and irregular
rather than continuously linear. Indeed, in roughly a
quarter of the cases, C3 was not detected at all, a point
recently reviewed [24, 25], and in contrast with immune
complex nephritis where C3 may predominate.
Lung tissue was available for immunofluorescent study
in three Goodpasture's patients and showed bright linear
deposits of IgG conforming to the distribution of the
alveolar basement membrane (Fig. 1) in two specimens
obtained at autopsy. The third patient had a lung biopsy
during a pericardiectomy one year postnephrectomy and
six months after the last episode of hemoptysis. This
biopsy contained no immunoglobulin deposits by immuno-
fluorescence.
Elution of antiGBM antibodies. Acid citrate eluates
containing antiGBM antibodies were obtained from
22 Goodpasture's and 12 non-Goodpasture's patients. The
amount of IgG eluted per gram of kidney varied widely,
ranging from 2 to 34 jsg/g of tissue. Sixteen of 19 (84%)
of these Goodpasture's eluates localized in vitro to Bow-
man's capsule and/or tubular basement membrane
in addition to binding to the GBM. When an eluate bound
to the TBM, it was confined to "islands" of tubules in all
but patient 26, in which all TBM was uniformly stained.
Eluates available from the non-Goodpasture's patients
reacted with Bowman's capsule and/or TBM in five of
nine instances (56%), but less intensely than did the
Goodpasture eluates. It is not known whether this reflects
differing quantities of total or active antibody [22], dif-
ferences in binding affinities of the eluted antibody or
broader basement membrane specificities of the Good-
pasture eluates as previously suggested [23].
Circulating antiGBM antibodies. Detection of circulating
antiGBM antibodies (usually in low titers) by indirect
immunofluorescence has proved to be a useful adjunct to
confirm the diagnosis of antiGBM nephritis and to monitor
the rate of disappearance of circulating antibodies prior
to transplantation. The test in principle is simple, involving
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Table 2. Patients with antiGBM antibody-induced glomerulonephritis and Goodpasture's syndrome (Abbreviations p. 79)
Patient
Diagnosis Initial
symptoms
Onset to
renal failure,
Immuno-
sup-
Bilateral
nephrec- Followup and course
If E Se (interval) months pression tomy
Sex!
age
1 Mf16 + + + Puld 14 none yes living 2 mo after Tx
(12 mo)
2 Mf18 + + + Pul
(I mo)
4 none no died 6 mo (septicemia, biopsy
wound infection)
3 Mf27 + + + Pul'
(3 mo)
9a
(neph)
S yese living 2 yr after Tx
4 M/38 + + + Rene
(1 mo)
2 S no died 3.5 mo (renal failure)
5 M/30 + + + Rene 3a SP yes living 3 yr after Tx
(0.2 mo)
6 M/20 + + + Simd Ia none yes living 18 mo on dialysis
7 M720 + + + Sim 2
(neph)
SA yes' living 9 mo after Tx
8 M/48 + + + Sim ia A yesc living 13 mo on dialysis
9 M/17 + + + Sim 1.5a S yese living 3 mo after Tx
10 Mf20 + + + Simd 1 5 no died 1.5 mo (renal failure)
11 M/34 + + NA Pul' 4 SA no died 6 mo (respiratory failure)
(2 mo)
12 M/18 + + NA Pul1
(0.5 mo)
none SPN no died 1.5 mo (repiratory failure)
13 M/28 + + NA Pul
(1 mo)
3a SA Ac no died 3.5 mo (respiratory failure)
14 M/51 + + 0 Ren1
(1.5 mo)
1.5 SA no living 2.5 yr
15 M/63 + + NA Sim' ia SC yes died 4 mo (coronary thrombosis)
16 M/18 + + NA SimU ba SA no died 12 mo (renal failure,
pancreatitis)
17 M/26 NA + NA Sim' 1.5a S yes living 4.5 yr after Tx
18 M/23 + NA + Pule iia ST yesh living 2.5 yr on dialysis
(7 mo)
19 M/20 + NA + Pule
(3 mo)
4a SP yes died after second Tx (intestinal
hemorrhage)
20 M/31 + NA + Rene
(1 mo)
l SA yesb living 12 mo on home dialysis
21 M/34 + NA + Sim 2 SA yesc died 2 mo after Tx (sepsis)
22 M/21 + NA 0 Pule
(2 mo)
none S no living 3 yr
23 M/27 + NA 0 Rent
(after Tx)
(13 mo)
5a S yesb died 1 mo after Tx (respiratory
failure)
24 M/26 + NA NA Rent
(3 mo)
3. S yesb died 24 hr after nephrectomy
(respiratory failure)
25 Mf20 NA NA + Sim 4a SA no died 8 mo (respiratory failure)
26 Ff42 + + + Pule
(1 mo)
2 none yes° died 6 mo (dialysis complications)
27 F/51 + + + Puld 2 SA yesh died 10 mo (dialysis complications)
(1 mo)
28 Ff18 0 + + Rene
(2 mo)
2 none yes living 6 mo after Tx
29 Ff21 NA + + Sim 2 S yesb died 4 mo (respiratory failure)
30 Ff19 + NA + Sime none SA no living 71/2 yr
31 Ff24 NA + NA Renr la S no died 7 wk (respiratory failure)
(1.5 mo)
32 Ff43 + NA NA Pul1
(0.8 mo)
none none no living 5 yr
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indirect immunofluorescent detection of test serum IgG
bound to the GBM of a normal human kidney section. It
has proved difficult, however, to find adequate normal
human renal tissue on which to perform this test. The
majority of "normal kidneys" (kidneys from autopsies,
untransplanted cadaver kidneys, infant kidneys, etc.)
contain enough IgG accentuation on the GBM to confuse
interpretation of the assay. Likewise, "normal kidneys"
vary in their reactivity with known positive serum samples,
making it imperative that known positive and negative
controls be interspersed throughout each series of test
samples. The most reliable sources of usable "normal
kidney" are in situ biopsies of nonnephritic nephrectomy
specimens (renal cyst, neoplasma, trauma, etc.). The use of
a radioimmunoassay for detection of antiOBM antibodies
[22] should obviate many of these problems.
The instance of positive reactions has increased some-
what [15] over the years, probably reflecting increased
experience as well as improved reagents and immuno-
fluorescent equipment. Only three of 23 (13%) of Good-
pasture's patients tested before or shortly after nephrectomy
were negative for circulating antiGBM antibodies. Circulat-
ing antiGBM antibodies have been easily detectable prior
to nephrectomy in most Goodpasture's patients, although
the titers may rise for a short time after nephrectomy.
Two Goodpasture's patients whose serial studies were
available exhibited a striking decrease in titers of circulating
antibodies before death (patient 4) or nephrectomy
(patient 5). The incidence of negative reactions was greater
in the non-Goodpasture's patients (six of 16 patients
tested, or 38%).
Serial serum samples were available from ten Good-
pasture's and three non-Goodpasture's patients so that
an estimate of the duration of their antiGBM response
after nephrectomy could be made. In the Goodpasture's
patients, detectable antiGBM antibodies (by indirect
immunofluorescence) had disappeared in 3 to 25 months
(mean eight months or six months if the 25-month duration
was excluded). The duration in the non-Goodpasture's
patients was 4 to 12 months (mean seven months).
AntiGBM antibodies and Goodpasture's syndrome. The
32 patients with antiGBM antibodies and Goodpasture's
syndrome are summarized in Table 2. Twenty-five were
males and ranged in age from 16 to 63 years (mean 28 years).
Seven were females and ranged in age from 19 to 52 years
(mean 31 years). Diagnoses were established by immuno-
fluorescence, elution of renal tissue and detection of
circulating antiGBM antibodies in 12 patients, a combina-
tion of two of these methods in 13 patients, elution studies
only in two patients and either immunofluorescence or
serum studies in five instances.
The presenting symptoms were pulmonary in 12 patients,
followed in 0.5 to 12 months (mean 2.9 months) by renal
abnormalities. In eight patients, onset of the disease with
renal symptoms was followed in 0.2 to 13 months (mean
three months) by pulmonary symptoms. In 12 cases,
pulmonary symptoms and renal abnormalities began
coincidentally. The pulmonary symptoms were mild,
moderate or severe in 22, 34 or 44% of patients, respectively.
Renal failure necessitating dialysis occurred within 1 to
14 months of onset (mean 3.5 months) in 26 patients;
two patients required dialysis after nephrectomy, which
was done in an attempt to control pulmonary hemorrhage.
Four patients did not develop sufficient renal failure to
require dialysis.
Bilateral nephrectomy was done in 19 patients, unilateral
nephrectomy was done in two patients for complications
resulting from biopsy and 11 patients did not receive
nephrectomy. Nephrectomy was judged to have been
helpful or life-saving in the management of pulmonary
hemorrhage in seven patients [26—28] (Table 3). Six patients
had continued hemoptysis and further pulmonary symptoms
after nephrectomy, severe enough in three instances to
contribute to death (one within 24 hours of nephrectomy
and one after transplantation). In analyzing the effects of
nephrectomy on pulmonary involvement in Goodpasture's
syndrome, one might wish to exclude the patient who died
within 24 hours as insufficiently followed and the patient
who was no longer anephric after transplantation. Another
of the surviving post-nephrectomy patients required
numerous hospitalizations for hemoptysis during the first
six months after nephrectomy. Of the 13 nonnephrectomy
or unilateral nephrectomy patients, five died from pulmo-
nary failure. These observations suggest a beneficial effect
of nephrectomy on the pulmonary manifestations of anti-
GBM antibody associated Goodpasture's syndrome in
some but not all patients. It must be borne in mind that
the data are retrospective and not controlled.
Non-Goodpasture's antiGBM antibody-induced glomerulo-
nephritis. The 21 patients with non-Goodpasture's antiGBM
nephritis are summarized in Table 4. Fourteen of the
patients were male and ranged in age from 5 to 42 years
(mean 21 years). The seven female patients in this group
were age 8 to 60 years (mean 28 years). The diagnoses
Abbreviations—Diagnosis: If, immunofluorescence; E, elution; Se, circulating antiGBM antibodies. Initial symptoms: Pul, pulmonary;
Ren, renal; Sim, simultaneous (interval between onset of either pulmonary or renal symptoms). Immunosuppression: 5, steroids;
A, azathioprine; P, 6-mercaptopurine; C, cyelophosphamide; Ac, actinomycin C; N, nitrogen mustrad; T, triethylenemelamine.
Other: M, male; F, female; Tx, transplantation; +, positive; 0, negative; NA, not available.
a Dialysis. d Mild pulmonary manifestation.
b Hemoptysis following nephrectomy. e Moderate pulmonary manifestation.
Nephreetomy thought to be of great benefit for respiratory manifestation. Severe pulmonary manifestation.
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Table 3. Effect of nephrectomy on patients with antiGBM antibody-related Goodpasture's syndrome
Patients living Patients deceased
Adequate Living Living Respiratory Renal Dialysis Trans-
renal on after failure failure sequela plantation
function dialysis trans- sequela
plantation
Nephrectomy 0 4 7 3ab 3 2
NoNephrectomy 4 0 0 5 1 3 0
a One patient died within 24 hours after nephrectomy.
One patient died after transplantation.
Table 4. Patients with antiGBM antibody-induced glomerulonephritis without Goodpasture's syndrome
Patient Sex/
age If
Diagnosis
E Se
Onset to
renal
failure
Bilateral
nephrec-
tomy
Immuno-
sup-
pression
Followup and course
33 M/20 + + + 1 moa yes no living 1 yr on dialysis
34 M/42 + + + 22 yra yes no died after second Tx (hemorrhage)
35 M/20 + + 0 9 moa yes SA died 12 mo after unsuccessful Tx
(overdose)
36 M/25 + + NA 18 moa yes S living 3 yr after Tx
37 M/25 + + NA 2 moa yes no living 5 yr after Tx
38 M/13 NA + 0 1 moa yes SA died after second Tx (cardiac arrest)
39 M/14 + NA + none no S living 1 yr with normal function
40 M/23 + NA + 5 moa yes no living 3 yr after Tx
41 M/24 + NA + 5 moa yes SC died 9 mo after Tx (sepsis)
42 M/20 + NA + 1 moa yes no living 11 mo after Tx
43 M/23 + NA NA 2 moa no A living 12 mo on dialysis
44 M/13 + NA 0 none no SA living 18 mo with normal function
45 M/5 + NA 0 none no SC living 7 yr with normal function
46 M/29 NA NA + 9 yra yes no living 4.5 yr after Tx
47 F/28 + + + 2 yra yes NA living 15 mo after Tx
48 F/22 + + 0 3 moa yes A died 10 mo after Tx (sepsis)
49 F/60 + + NA 0.1 moa yes A died after 18 mo on home dialysis
(hyperkalemia)
50 F/16 0 + + 2 moa yes no living 2 mo after Tx
51 F/23 NA + + 2 moa yes SA died 8 mo after Tx (sepsis)
52 F/8 NA + NA 9 moa yes SA living 5 yr after Tx
53 F/40 + NA 0 10 yra yes NA died after second Tx (sepsis)
Abbreviations—Diagnosis: If, immunofluorescence; E, elution; Se, circulating antiGfiM antibodies. Immunosuppression: 5, steroids;
A, azathioprine; C, cyclophosphamide. Other: M, male; F, female; NA, not available; Tx, transplantation; +, positive; 0, negative.
a Dialysis.
were based on immunofluoreseence, elution and serum
studies in three, on a combination of two of these in 11,
elution studies only in two and either immunofluorescence
or serum studies in five patients.
Fourteen of the patients had a rapidly progressive
course to renal failure requiring dialysis in 0.1 to 18 months
(mean 4.3 months). Four additional patients had chronic
glomerulonephritis with courses of 22, ten, nine and two
years before renal failure. Three patients did not develop
severe renal insufficiency. One of these (patient 39) had
linear staining of the glomeruli of a renal biopsy taken
during splenectomy for hypersplenism and a diagnostic
workup for optic vasculitis. Another (patient 45) had
steroid-dependent nephrotic syndrome which eventually
cleared after a course of cyclophosphamide. A third
(patient 44) had acute glomerulonephritis with nephrotic
syndrome and mild renal insufficiency responding to
prednisone and azathioprine.
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Presenting clinical illness
hemoptysis
dyspnea
weakness
fever
gross hematuria
dysuria
oliguria, anuria
increased nocturia
nausea, vomiting, diarrhea,
weight loss
edema
Antecedent infection
sore throat, respiratory
infection
flu syndrome
Past medical history
pulmonary disease
renal disease/hypertension
diabetes
Family history
renal or pulmonary disease
Physicalfindings
fundal abnormalities
blood pressure 140/90 or
greater
diastolic 110
or greater
pallor
rales-rhonchi
cardiomegaly
cardiac murmur
hepato-splenomegaly
abdominal or costoverte-
bral angle tenderness
edema
14/32 (44%) 6/20 (30%)
5/32 (17%) 2/20 (10%)
Laboratory investigations
hemoglobin, mean
<10.5 g-%
hematocrit, mean
31% vol or less
white blood cell count mean
10,000/mm3 or more
>75% polymorphonuclear
leukocytes
>4% eosinophils
reticulocytes> 1%
platelet count< 150,000/mm3
throat culture positive for
streptococci
antistreptolysin 0 titer> 250
proteinuria
hematuria
abnormal urinary sediment
24-hour urinary protein
excretion, mean
elevated blood urea
nitrogen and/or creatinine
blood sugar> 140 mg-%
bilateral radiographic
chest infiltrates
sputum hemosiderin-laden
macrophages
decreased serum comple-
ment
positive antinuclear anti-
bodies (low titer)
liver functional abnormalities
clotting abnormalities
Of the 18 patients developing renal failure, three are
living on dialysis, eight are alive after transplantation and
seven have died while on dialysis or after one or two
transplants.
Clinical manifestations of patients with Goodpasture's
syndrome and non-Goodpasture's antiGBM antibody-induced
glomerulonephritis. The clinical manifestations of patients
with Goodpasture's and non-Goodpasture's antiGBM
nephritis are summarized in Table 5. Respiratory or flulike
anticedent illnesses were recorded in 61 and 40% of the
Goodpasture's and non-Goodpasture's patients, respec-
tively. It is unknown if these were true infectious illnesses
or were in part prodromal symptomatology. Antiviral
antibody levels were titered in six Goodpasture's patients
and rising titers of influenza A2 antibodies were found in
two patients [29], accompanied by influenza A2 virus
isolation in one (patient 8). Antiviral antibody studies
were negative in the one non-Goodpasture's patient in
whom they were performed. Streptococcal infections were
not documented by culture in the Goodpasture's patients
and were identified in only 20% of the non-Goodpasture's
cases. Four of the non-Goodpasture's patients developed
their illnesses while stationed in Vietnam, and at least
one was known to have undergone therapy for malaria
(P.falciparum) during the initial phase of his illness.
Histories of hydrocarbon-solvent exposure [30] were not
systematically obtained from the patients in this series;
however, one Goodpasture's patient was an auto service
station employee for one year.
The presenting symptomatology was similar in the
Goodpasture's and non-Goodpasture's patients aside
from the pulmonary features which distinguished their
conditions. The patients in general had been free of pul-
monary or renal disease/hypertension, although the non-
Table 5. Clinical features of patients with antiGBM antibody-related Goodpasture's syndrome and non-Goodpasture's glomerulo-
nephritis
Goodpasture'sClinical feature
patients
Non-
Goodpasture's
patients
Goodpasture'sClinical feature
patients
Non-
Goodpasture's
patients
23/32 (72%)
14/32 (44%)
10/32 (31%)
5/32 (17%)
13/32 (41%)
2/32 (6%)
3/32 (9%)
6/32 (19%)
14/32 (44%)
5/32 (17%)
0/18 (0%)
2/18 (11%)
7/18 (39%)
2/18 (11%)
8/18 (44%)
2/18 (11%)
2/18 (11%)
2/18 (11%)
10/18 (55%)
8/18 (44%)
6.6g%
27/27 (100%)
20 vol%
25/25 (100%)
12,200/mm3
14/22 (64%)
14/17 (82%)
2/17 (12%)
9/11 (82%)
4/18 (22%)
0/14 (0%)
1/20 (5%)
32/32 (100%)
32/32 (100%)
32/32 (100%)
8.5 g%
9/14 (64%)
23 vol%
15/18 (83%)
8,100/mm3
5/19 (26%)
3/15 (20%)
8/16 (50%)
4/6 (67%)
3/15 (20%)
2/8 (25%)
4/14 (29%)
19/20 (95%)
19/20 (95%)
19/20 (95%)
2/29 (7%)
4/29 (14%)
0/28 (0%)
1/18 (6%)
5/18 (28%)
1/18 (6%)
4/27 (15%) 2/18 (11%) 3.4g 7.9g
8/24 (33%)
17/30 (57%)
5/30 (17%)
22/29 (76%)
14/30 (47%)
4/30 (13%)
8/29 (28%)
6/30 (20%)
5/30 (17%)
8/30 (27%)
28/31 (90%)
3/16 (19%)5/17 (29%)
10/19 (53/)
4/19 (21%)
10/19 (53%)
3/19 (16%)
5/19 (26%)
9/19 (47%)
5/19 (26%)
2/19 (11%)
9/19 (47%)
18/20 (90%)
6/18 (33%)
23/26 (88%) 0/17 (0%)
9/11 (82%) 0/2 (0%)
1/11 (9%) 1/8 (13%)
1/21 (5%)
3/19 (16%)
2/10 (20%)
3/10 (30%)
1/8 (13%)
1/6 (17%)
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Fig. 2. A) Severe and extensive alterations of all glomeruli (arrows) are evident in this low power photomicrograph of the nephrectomized
kidney from patient 9. The glomerular reaction is accompanied by widespread tubular changes and interstitial cellular infiltrates (he-
matoxylin and eosin, original magnification x 160). B) A high power photomicrograph of the glomerular alterations seen in patient 9.
Extensive crescent formation is evident with necrosis of the remaining portion of the glomerular tuft. Polymorphonuclear leukocytes
are not a prominent feature of this lesion, which on immunofluorescent examination contained little or no C3 although intense linear
IgG deposits were present (hematoxylin and eosin, original magnification x 320). C) A low power photomicrograph of lung tissue
obtained at autopsy from patient 31 shows the widespread alveolar and interstitial hemorrhage which was present throughout the available
sections (hematoxylin and eosin, original magnification x 160). D) A high power photomicrograph of the tissue in C showing the prescence
of large numbers of hemosiderin-laden macrophages in the areas of hemorrhage (hematoxylin and eosin, original magnification X 320).
Goodpasture's patients had a 28 % incidence of preceding
renal disease and/or hypertension. Few patients had family
histories of pulmonary or renal disease; however, a cousin
of one Goodpasture's patient was said to have had Good-
pasture's syndrome.
Physical and laboratory findings reflected the pulmonary
features of the Goodpasture's patients with frequent
rales/rhonchi, pallor, more severe anemia and a greater
reticulocyte response. The Goodpasture's patients more
often had leukocytosis with increased circulating poly-
morphonuclear leukocytes. One-half of the non-Good-
pasture's patients had eosinophilia. Hypertension was
present in slightly more than half of both groups, but was
severe in only about 20%. Proteinuria was greater in the
non-Goodpasture's patients, and edema was more frequent.
Serum albumin was below 3 g/l0O ml in four of nine Good-
pasture's and five of nine non-Goodpasture's patients.
Two of the non-Goodpasture's patients had recorded
elevations in serum cholesterol; however, the number of
observations was small in both groups. Jaundice was not
evident in either group, and minor liver functional ab-
normalities were recorded in only a few patients.
The renal histologic alterations in both Goodpasture's
and non-Goodpasture's patients were similar and with
few exceptions were described as active proliferative
often necrotizing cresent-forming types of glomerulonephri-
tis with variable, probably secondary, tubular alterations
accompanied by interstitial infiltrative processes. in some
instances, membranous thickening of the GBM was
described. Renal histologic sections were available for
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study from 11 Goodpasture's and six non-Goodpasture's
patients. A very active necrotizing proliferative glomerulo-
nephritis with extensive crescent formation (Fig. 2) was
observed in nine of the Goodpasture's and two of the
non-Goodpasture's patients, each of whom had had a
rapidly progressive course (mean three months) to renal
failure. Two of the patients with Goodpasture's syndrome
surviving with adequate renal function had, as would be
expected, much less severe renal alterations. One (patient 14)
had mild-to-moderate proliferative changes with focal
sclerosis of some glomerular tufts, occasional residual
crescent formation as well as infrequent completely hyalin-
ized glomeruli. The other (patient 32) had only a mild-to-
moderate increase in glomerular cellularity with poly-
morphonuclear leukocyte infiltration. In three non-Good-
pasture's patients with prolonged courses, histologic
findings were more consistent with chronic glomerulo-
nephritis typified by membranous thickening of the GBM,
much less proliferation and large numbers of hyalinized
glomeruli. Severe tubular atrophy and large numbers of
dilated renal tubules were also present in these kidneys,
accompanied by varying degrees of interstitial cellular
infiltration. One non-Goodpasture's patient (number 45)
with steroid dependent nephrotic syndrome had minimal
glomerular alterations.
The pulmonary pathology in the Goodpasture's patients
was typified by patient 31 (Fig. 2). Tn this specimen obtained
at autopsy, severe hemorrhage was encountered in the
interstitium and in alveoli. Polymorphonuclear leukocytes
were present in moderate numbers in the interstitium, and
numerous hemosiderin-laden macrophages were present
in the alveoli. Insufficient serial samples were available
from either lungs or kidneys to make any meaningful
comment regarding the evolution of the final pathological
picture.
Effects of immunosuppression in Goodpasture's syndrome
and non-Goodpasture's antiGBM antibody-induced gb-
merulonephritis. Twenty-six of the 32 Goodpasture's
patients received immunosuppression in the form of:
steroids (24 patients), azathioprine (11 patients), triethylene-
melamine (one patient), 6-mercaptopurine (three patients),
cyclophosphamide (one patient), actinomycin C (one
patient) and nitrogen mustard (one patient) (Table 2).
Dosage and length of administration varied, and the effect
of the immunosuppressive treatment could not be easily
separated from the concomitant supportive therapy and
effects of nephrectomy. Some improvement, most frequent
in the pulmonary manifestations, was attributed to the
steroid therapy in eight patients in doses equivalent to
15 to 160 mg of prednisone per day (mean 85 mg). Three
of the four patients surviving with adequate renal function
were in this group. Azathioprine was felt to be helpful in
three instances, including one patient who survived with
adequate renal function. Of the other immunosuppressive
drugs tried, only the triethylenemelamine used in patient 18
was considered beneficial when hemoptysis which had
persisted for six months after nephrectomy abated coinci-
dently with its administration. In summary, then, of the
26 Goodpasture's patients receiving immunosuppression
in one form or another, three retained adequate renal
function, eight are living on dialysis or after transplantation
and 15 succumbed to the disease process or after dialysis
or transplantation was required.
Eleven of the non-Goodpasture's patients received
immunosuppression (steroids, nine patients; azathioprine,
eight patients; and cyclophosphamide, two patients)
(Table 4). The steroid dose ranged from 5 to 300 mg of
prednisone equivalents per day (mean 95 mg). Steroids
alone (patient 39) or with azathioprine (patient 44) and
cyclophosphamide (patient 45) were used in the three
patients retaining adequate renal function. Three other
immunosuppressed patients are living on dialysis or
after transplantation, while five succumbed. In this group,
as in the Goodpasture's patients, it was difficult to ascribe
the outcomes to a single event; in general, the results
were not gratifying, with the patients pursuing what
appeared to be the course predetermined by the magnitude
and tempo of the immunologic reaction.
Renal transplantation in Goodpasture's syndrome and
non-Goodpasture's antiGBM antibody-induced gbomerubo-
nephritis (Table 6). Nine patients with Goodpasture's
syndrome received renal transplants from a living related
donor after anephric periods of one to nine months.
Patient 19 received a transplant from his father one month
after nephrectomy while circulating antiGBM antibodies
were still detectable. The transplant developed severe
antiGBM nephritis confirmed by immunofluorescence,
elution and serum studies and was removed in one month.
After one year, when circulating antiGBM antibodies
were no longer detectable by indirect immunofluorescence
or perfusion of subhuman primate kidneys, the patient
was transplanted with a kidney from a cadaver. This
second transplant assumed partial function after a pro-
longed period of anuria (creatinine 4.2 mg/l00 ml).
Immunofluorescent evidence of recurrent nephritis was
found in two other patients transplanted five and eight
months after nephrectomy when circulating antiGBM
antibodies were no longer detectable. Patient 23 retained
renal function until immunosuppression was withdrawn
in an effort to control possible infectious contribution to
the pulmonary failure which resulted in his death one
month posttransplantation. The transplant contained
linear glomerular TgG deposits accompanied by lesser
amounts of C 3. Patient 28, transplanted eight months
after nephrectomy when circulating antiGBM antibodies
were thought to have disappeared, had linear glomerular
IgG deposits when biopsied for investigation of mild
azotemia six months after transplantation. The remaining
Goodpasture's patients have no clinical evidence of recur-
rent nephritis. Four of these patients have had negative
posttransplant immunofluorescent biopsies, including pa-
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Table 6. Transplantation in patients with Goodpasture's and non-Goodpasture's antiGBM antibody-induced glomerulonephritis
Ant jGBM Trans- Clinical Transplant
Patient Anephric antibody plant Tissue Rejection recurrent diagnosis Follow-
period at Tx source match anuria nephritis up Function Outcome
Goodpasture's syndrome
If E Se
1 9 mo 0 (S) (P) father NA
3 5 moa 0 (S) brother A
5 3 rno 0 (S) brother A
7 6 moa 0 (S) mother NA
17 6 wk NA sister NA
19 1 nio + (S) father B
1 yr 0 (P) cadaver B
21 5 moa 0 (S) mother D
23 5 mo 0 (S) father B
28 8 moa "0" (S) sister NA
Non-Goodpasture's glomerulonephritis
no none 2 mo Cr 2.5 living
NA no 0 NA 0 2 yr normal living
NA no 0 NA 0 3 yr normal living
no no "0" NA NA 9 mo CrCl 60 living
no no none 4.5 yr Cr 1.2 living
NA yes + + + 1 mo none removed
anuria no none 7 mo Cr 4.2 died (GI
55 da hemorrhage)
1 no 0 0 0 2 mo rejection died (sepsis)
1 no + NA 0 1 mo rejection died (pulmonary
(failure)
NA probable "+" NA NA 20 mo Cr 2.4 living
36 oa NA father A—
37 Ø NA brother B
38 0 0 mother C
0 NA cadaver D
40 4 mo 0 (S) father 2A
41 1 wka NA brother B
42 6 mo 0 cadaver 32%
mis-
46 2 mo + (S) brother NA
47 1 mo + (S) mother NA
48 8 mo 0 (S) mother C
50 1 moa NA cadaver D
51 3 mo NA father NA
52 0 NA mother NA
53 0 NA mother NA
hyper- NA none
acute
anuric
hyper. NA none
acute
anuric
none
lb no none
no none
NA yes none
2 da anuric died (hemor-
rhage)
3 yr CrCl 77 living
3 yr CrC! 55 living
3.3 yr no 1st Tx not
Abbreviations— Detection of antiGBM antibody at transplantation: S, circulating antiGBM antibodies (indirect immunofluorescence);
P, perfusion. Transplant immunopathologic diagnosis: If, immunofluorescence; E, elution; Se, circulating antiGBM antibodies.
Other: +, positive; 0, negative; NA, not available; Tx, transplantation;" ", study done elsewhere; CrCl, creatinine clearance (mi/mm);
Cr, serum creatinine (mg%); prot, protein.
a Splenectomy.
Rejection responded to therapy.
34 2 wk + (S) sister F
2 mo NA cadaver F
35 3 mo 0 (S) cadaver B
1,5 mo anuric removed
yes + NA 0 4 mo 20 g Tx removed;
prot/24 hr died (overdose)
CrC! 5
match
function removed;
re-Tx in 3 yr
NA no none 4 mo CrC! 10 died (cardiac
arrest)
no NA NA 0 15 mo Cr 1.1 living
none no none 9 mo Cr 1.2 died (viral
sepsis)
yes + NA 0 11 mo CrC1 50 living
Cr 1.6
yes + NA 0 4.5 yr CrC! 70 livingl no none 15 mo normal living
4 no none 10 mo CrC! 5 died (sepsis)
1' no NA NA + 1 yr Cr 0.5 living
yes no none 8 mo NA died (sepsis)
NA yes none 6 yr CrC! 31 living
hyper- NA + NA 0 8 da anuric 2nd Tx 1 dalater
acute
anuric
hyper. NA + NA 0 7 da anuric died (sepsis)
acute
anuric
0 NA cadaver NA
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Table 7. Ant1GBM antibodies in renal transplants from patients without pretranspiantation immunopathologic studies
Bilateral
Pa- Sex! Diagnosis Original nephrec- Trans- Clinical Trans-
tient age
If E Se
disease tomy
(anephric
period)
plant
source
Tissue Rejection Biopsy
match episodes
GN
(dura-
tion)
plant Followup
func- and course
tion
54 M22 + + NA CGN yesa mother B ?acute 1 mo yes
(1 mo)
CrC1 28 Txremoved;
died 5 wk
after Tx
55 M11 + NA + RPGN yesa
(1 wk)
yes
(4 mo)
father
mother
NA 2—3' 1 mo
NA 23b no
yes
(6 mo)
no
failed Tx removed
2.5 yr
CrCl 55 living 1 yr
after second
Tx
56 M,'27 + NA 0 CGN yes brother B NA 2 yr no CrC1 150 living 5 yr
after Tx
57 M33 + NA 0 CON yesa brother B none 2.5 yr no normal living 5 yr
after Tx
58 M!26 + NA 0 CGN no cadaver NA 2b 8 mo yes
(8 mo)
CrCI 34 living 2 yr
after Tx
59 Ml9 + NA NA RPGN yesa brother A 1 mo yes
(12 mo)
CrCI 84 living 4 yr
after Tx
60 M!22 + NA NA CN yes
(1 mo)
mother NA multipleb 3.5 yr ?(NA) Cr 2.0 living 6 yr
after Tx
61 F!13 +
+
+
+
NA
NA
+
+
NA
RPGN 3 mo
NA
NA
mother
cadaver
cadaver
NA NA 15 mo
NA NA 13 mo
NA hyper- —
acute
yes
(lSmo)
yes
(13 mo)
yes
failed Tx removed
lSmo
failed Tx removed
13 mo
failed expired
62 F!20 + NA 0 CGN yesa
(0)
brother B+ 1b 3 yr no CrCl 72 living 5 yr
after Tx
63 F!25 + NA NA CGN yesa brother A l 19 mo yes
(NA)
CrC1 126 living 4.5 yr
after Tx
Abbreviations—Diagnosis: If, immunofluorescence; E, elution; Se, circulating antiGBM antibodies. Original disease: CGN, chronic
glomerulonephritis; RPGN, rapidly progressive glomerulonephritis; CN, cortical necrosis. Other: Tx, transplantation; CrCl, creatinine
clearance (ml!min); Cr, serum creatinine (mg%); +, positive; 0, negative; NA, not available; GN, glomerulonephritis.
a Splenectomy.
b Rejection responded to therapy.
tient 21 who had severe rejection when immunosuppression
was withdrawn in an attempt to control fatal sepsis two
months after transplantation.
Fifteen of the non-Goodpasture's patients had renal
transplants, and six of these developed clinical or immuno-
fluorescent evidence of recurrent nephritis. Patient 53 had
two "hyperacute" rejections with linear IgG deposits in
both kidneys. In addition, patient 34, with circulating
antiGBM antibodies prior to transplantation, hyperacutely
rejected two transplants, but no immunopathologic
studies were done to demonstrate possible GBM binding
of circulating antibody. As in Goodpasture's patients,
linear glomerular IgG deposits were found in the transplant
of one patient who had no detectable circulating antiGBM
antibodies prior to transplantation (three months anephric
period). This suggests that the indirect immunofluorescent
assay may be too insensitive to detect low levels of circulat-
ing antibodies. Perfusion experiments using either human
or subhuman primate kidneys appear to be somewhat
more sensitive and offer the advantage of having sufficient
tissue for confirmatory elution studies. An alternate
explanation for the reappearance of antiGBM antibodies
would be a reactivation of the immune response by antigenic
material from the transplant.
In contrast to the Goodpasture's patients, two patients
(numbers 47 and 50) without clinical evidence of recurrent
nephritis had circulating antibodies revealed by indirect
immunofluorescence, one before and one just after trans-
plantation (anephric periods of one month). The deter-
mination of circulating antibodies shortly after transplanta-
tion without clinical evidence of nephritis in patient 50
ould suggest little binding to the transplant; however,
no immunopathologic studies were available to confirm
this speculation.
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AntiGBM antibodies in renal transplants from patients
lacking prior immunopathologic studies. Biopsies from
ten initial renal transplants (one month to 3.5 years post-
transplantation) in patients lacking pretransplant immuno-
pathologic characterization were found to contain linear
deposits of IgG (Table 7). Nine of the patients had gb-
merulonephritis as an antecedent illness (three rapidly
progressive and six chronic), while one (patient 60) had
lost renal function from cortical necrosis associated with
trauma [31]. The patients' age and sex distributions were
similar to those in Goodpasture's and non-Goodpasture's
groups described in the preceding sections. Development
of glomerulonephritis in the transplant was suspected or
questioned on the basis of unusual proteinuria and/or
hematuria in seven patients. One of the patients developed
antiGBM glomerulonephritis in two subsequent transplants
as well [31]. The presence of antiGBM nephritis indicated
by linear glomerular deposits of IgG by immunofluorescence
was confirmed in three of the patients by elution studies
or detection of circulating antiGBM antibodies. The
glomerular injury in five transplants in three of the patients
was severe enough to cause graft failure, necessitating
transplant removal. In the remaining four patients, the
clinical glomerular injury persisted eight to twelve months
(when recorded) and then diminished so that the patients
are living with adequate renal function four to six years
posttransplantation. Three patients without clinical suspi-
cion of glomerulonephritis were found to have linear
glomerular IgG deposits, and in two of these, linear C3
deposits were also apparent. Although these three patients
had received equine antihuman lymphocyte globulin [32],
no equine gamma globulin deposits were found. Normal
renal function has remained for an additional two to three
years since biopsy of the transplant.
Discussion
AntiGBM antibody-induced glomerulonephritis is a
clearly established entity which is responsible for about
5% of human glomerulonephritides, and for unknown
reasons is most common in young males. The only other
species known to have spontaneous antiGBM antibody-
induced glomerulonephritis is the horse [33]. Diagnosis is
based on immunofluorescent detection of antibodies
bound to the GBM and should be confirmed when possible
by elution studies or detection of circulating antibodies
to exclude "nonspecific" linear deposits that are some-
times identified in autopsied or perfused kidneys in which
an unusual nonimmunologic affinity of the GBM for IgG
seems to be manifest and possibly in kidneys from patients
with lupus erythematosus and diabetes [19, 21]. We would
suggest that the detection of antiGBM antibodies become
an essential feature in the diagnosis of Goodpasture's
syndrome and that eventually the term Goodpasture's
syndrome be replaced by the more exacting and etiologically
descriptive term of "anti-basement membrane antibody-
induced glomerulonephritis and pulmonary hemorrhage."
Such a designation conveys the pathogenetic role of anti-
basement membrane antibodies [3—5, 23, 34—361 in the
production of the often fulminant pulmonary hemorrhage
seen almost exclusively in Goodpasture's syndrome [24].
Although the presence of antiGBM antibodies is the
central event in initiating the glomerulonephritis and
probably pulmonary hemorrhage of Goodpasture's syn-
drome, the mechanism of mediation of this tissue damage
has not been well defined in man. Complement activation
and polymorphonuclear leukocyte participation appear
to be involved 75% of the time. However, the apparent
absence of complement activation in the remaining cases,
as suggested by normal serum complement and the lack of
detectable (immunofl uorescence) complement in glomeruli,
suggests that the injury in these cases may be mediated
by poorly understood pathways similar to those utilized
by avian [37, 38] and certain mammalian nephrotoxic
antiGBM sera [39] which do not appear to depend upon
complement activation and subsequent polymorphonuclear
leukocyte participation [40] to cause tissue injury.
While the participation of antibodies in antiGBM
glomerulonephritis is reasonably well understood, little
is known about the events that trigger the production of
antiGBM antibodies. Environmental factors might be
important in several ways. First, antigens such as the
influenza A2 virus might induce antibodies cross-reactive
with the basement membrane structures [29]. Second,
infectious agents or chemical substances such as hydro-
carbon solvents [30] might uncover or alter self-antigen
in such a way that they are rendered immunogenic. Third,
it is possible that environmental factors may work in a
nonantigenic way, as, for example, noxious stimuli (infec-
tious or chemical) might alter the anatomical integrity of
the lung and expose basement membrane antigens normally
sequestered from the circulation, thereby allowing anti-
GBM antibodies formed in response to an unrelated event
to interact with the lung to produce injury. All of these
ideas are speculative.
The antigenic stimulus responsible for antiGBM antibody
production might also originate from within the host.
Materials cross-reactive with the GBM are present in
normal urine and accumulate in serum after nephrectomy
[36, 41]. This suggests that the urinary basement membrane
antigens in part arise from basement membrane turnover
throughout the body and are normally excreted into the
urine. The observation that the urinary basement membrane
antigens are capable of inducing antiGBM antibody
glomerulonephri tis when reintroduced into experimental
animals [42] implies their potential autoantigenicity. As
work progresses toward isolation, purification and charac-
terization of the specific basement membrane antigens
involved, the possible etiologic significance of these sub-
stances may become clearer.
The unpredictable response of Goodpasture's patients
(with and without [43, 44] demonstrated antiGBM anti-
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bodies) to bilateral nephrectomy is difficult to evaluate
and suggests that a number of processes may be involved.
It is even difficult to dissociate the influences of nephrectomy
and of general supportive measures: dialysis, anesthesia
and immunosuppression on the improved patients. The
immunologic consequences of nephrectomy should be
reflected by an increased titer of circulating antiGBM
antibodies since the target tissue is removed, and an
increased amount of circulating basement membrane
antigens since their normal route of excretion is eliminated.
The effect of nephrectomy may depend upon the balance
of these two consequences. An increased antiGBM anti-
body level would be expected to increase the injury in the
lung. Increased circulating basement membrane antigens
might serve to combine with and neutralize antiGBM
antibodies, thereby protecting the lung. Serial measure-
ment of basement membrane antigens and antiGBM
antibodies in the blood pre- and postnephrectomy should
answer these questions.
Renal transplantation was reasonably successful in
patients discussed herein [26, 27] and has been reported
in other patients with clinical pictures of Goodpasture's
syndrome [43—45]. Evidence of glomerulonephritis after
grafting was present in three of nine, six or possibly seven
of 15, and ten of ten Goodpasture's, non-Goodpasture's
and previously uncharacterized (immunopathogenesis)
patients, respectively. The glomerulonephritis resulted in
graft failure in one Goodpasture's patient, three or possibly
four non-Goodpasture's patients and three uncharacterized
patients, whereas the remaining patients maintained renal
function, possibly related to concomitant immunosuppres-
sion. Severe recurrences seemed related most often to the
presence of circulating antiGBM antibodies and relatively
short or no anephric periods prior to transplantation.
Only one of 11 anephric patients with undetectable anti-
GBM antibodies developed severe recurrence. It would
then seem most reasonable to maintain patients with
evidence of antiGBM nephritis requiring transplantation
in an anephric state for several months during which
antiGBM antibody production is allowed to subside.
When they received transplants after this period, severe
recurrent glomerulonephritis resulting in graft failure
would appear unlikely.
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